期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Electrocardiographic Safety of Daily Hydroxychloroquine 400 mg Plus Azithromycin 250 mg as an Ambulatory Treatment for COVID-19 Patients in Cameroon
1
作者 Liliane Mfeukeu-Kuate William Djomo Ngatchou +26 位作者 Mazou Ngou Temgoua Charles Kouanfack Daniel Lemoungoum Joel Noutakdie Tochie Armel Zemsi Lauriane Fomete Skinner Lekelem Sylvain Zemsi Joelle Sobngwi Thierry Ntandzi Christian Ngongang Ouankou Yves Wasnyo Antoinette Tsama Assiga Jan René Nkeck Ahmadou Musa Jingi magellan guewo Eric Walter Pefura Yone Charlotte Moussi Omgba Paul Owono Etoundi Jean Cyr Yombi Samuel Kingue Alain Menanga Jacqueline Ze Minkande Pierre Ongolo Zogo Jean Claude Mbanya Pierre Joseph Fouda Eugène Sobngwi 《World Journal of Cardiovascular Diseases》 2021年第2期106-112,共7页
<strong>Objective:</strong> <span style="font-family:Verdana;">To determine the early electrocardiographic changes in a cohort of ambulatory cameroonian COVID-19 patients treated with hydro... <strong>Objective:</strong> <span style="font-family:Verdana;">To determine the early electrocardiographic changes in a cohort of ambulatory cameroonian COVID-19 patients treated with hydroxychlo</span><span style="font-family:Verdana;">- </span><span style="font-family:;" "=""><span style="font-family:Verdana;">roquine and Azithromycin. </span><b><span style="font-family:Verdana;">Design:</span></b><span style="font-family:Verdana;"> Prospective study. </span><b><span style="font-family:Verdana;">Setting:</span></b><span style="font-family:Verdana;"> Treatment centres of the city of Yaounde, Cameroon, from May 7</span><sup><span style="font-size:12px;font-family:Verdana;">th</span></sup><span style="font-family:Verdana;"> to 24</span><sup><span style="font-size:12px;font-family:Verdana;">th</span></sup><span style="font-family:Verdana;"> 2020. </span><b><span style="font-family:Verdana;">Participants:</span></b><span style="font-family:Verdana;"> We enrolled 51 consecutive confirmed COVID-19 on RT-PCR who having mild forms of COVID-19 and treated by hydroxychloroquine 200</span></span><span style="font-family:Verdana;"> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">mg twice daily during seven #days plus Azithromycin 500 mg the first day and 250 mg the remaining 4 days as per national standard. </span><b><span style="font-family:Verdana;">Main Outcomes Measures:</span></b><span style="font-family:Verdana;"> The</span><b><span style="font-family:Verdana;"> </span></b><span style="font-family:Verdana;">primary end-point was the change in QTc interval between day 0 (D0), day 3 (D3) and day 7 (D7). Secondary endpoints were changes in all other cardiac electrical conductivity patterns and the occurrence of clinical arrhythmic events during the course of treatment. </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">The population (29 men and 22 women) was aged 39 ± 11 years (range 17 to 61 years). Mean Tisdale score was 3.35 ± 0.48. No significant change from baseline (D0) of QTc was observed at D7 (429 ± 27 ms at D0 versus 396 ± 26 ms at D7;p = 0.27). A reduction of heart rate was observed between the D0 and D7 (75 ± 13 bpm versus 70 ± 13 bpm, p = 0.02) with increased QRS duration between D0 and D7 (95 ± 10 ms versus 102 ± 17 ms, p = 0.004). No symptomatic arrhythmic events occurred during the treatment course. </span><b><span style="font-family:Verdana;">Conclusions: </span></b><span style="font-family:Verdana;">No life-threatening modification of the QT interval was observed in non-severe COVID-19 patients treated ambulatory with hydroxychloroquine and azith</span></span><span style="font-family:Verdana;">romycin. Studies are needed in critical-ill and older patients.</span> 展开更多
关键词 Early Electrocardiographic Changes COVID-19 HYDROXYCHLOROQUINE AZITHROMYCIN Cameroon
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部